StarkAge Therapeutics (SATx) is a privately held discovery-stage biotechnology company based from Lille, France. The company was emerged from the idea of eliminating disease specific senescent cells with immunotherapies.

Selective destruction of senescent cells enables successfull clinical outcomes and longer lifespan. Its proprietary biomarker discovery platform, ExoCiseTM, enabling the characterization of senescent cells biomarkers from patient derived extracellular vesicles and their specific validation for each disease.

It aims to delay or stop disease progression and improve quality of life in patients with age-related diseases.